 |
|
|
| |
SILEN-C1: Early Antiviral Activity and Safety of
BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2009, Boston, MA
Mark S. Sulkowski1, Peter Ferenci2, Ceasu Emanoil3, Tarik Asselah4, Caruntu Florin Alexandru5, Jacob Lalezari6, Marc Bourlere7, Stefan Mauss8, Jean-Didier Grange9, Thomas Berg10, Stefan Zeuzem11, Adrian Streinu-Cercel12, David Wright13, Donald M. Jensen14, Carla Hafner15, Yakiv Datsenko15, Jerry O. Stern16, Gerhard Nehmiz15, and Gerhard Steinmann15
On behalf of the SILEN-C1 study group
1Johns Hopkins University, Baltimore, USA; 2Medical University, Wien, Austria; 3Hospital for Infectious and Tropical Diseases, Bucharest, Romania; 4Hopital Beaujon, Clichy Cedex, France; 5Institute of Infectious Diseases 1, Bucharest, Romania; 6Quest Clinical Research, San Francisco, USA; 7Hopital Saint Joseph, Marseille, France; 8Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 9Hopital TENON, Paris, France; 10Charité, Campus Virchow-Klinikum, Berlin, Germany; 11J.W. Goethe University Hospital, Frankfurt am Main, Germany; 12Institute of Infectious Diseases 1, Bucharest, Romania; 13Central Texas Clinical Research, Austin, USA; 14University of Chicago Hospitals, Chicago, USA; 15Boehringer Ingelheim Pharma, Biberach, Germany; 16Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA
|
| |
|
|
|
|
|
